Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds

by Zacks Equity Research Published on December 19,2018

Small drugmakers, in general, are having a decent year, despite failures of key pipeline candidates in pivotal studies.

• ORINY Quick QuoteORINYNo Net Change
• MDWD Quick QuoteMDWDPositive Net Change
• HKMPF Quick QuoteHKMPFNo Net Change
• ESALY Quick QuoteESALYPositive Net Change
• CPIX Quick QuoteCPIXNegative Net Change
• BSTC Quick QuoteBSTCPositive Net Change

• pharmaceuticals

Neurocrine (NBIX) Catches Eye: Stock Jumps 6.5%

by Zacks Equity Research Published on November 16,2018

Neurocrine (NBIX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

• NBIX Quick QuoteNBIXNegative Net Change
• ESALY Quick QuoteESALYPositive Net Change

• medical

Karyopharm Initiates NDA Submission Process for Selinexor

by Zacks Equity Research Published on July 19,2018

Karyopharm Therapeutics (KPTI) initiates rolling submission of a New Drug Application to the FDA with a request for accelerated approval for selinexor.

• ALXN Quick QuoteALXNPositive Net Change
• ILMN Quick QuoteILMNNegative Net Change
• ESALY Quick QuoteESALYPositive Net Change
• KPTI Quick QuoteKPTINegative Net Change

J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)

by Zacks Equity Research Published on July 18,2018

A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

• JNJ Quick QuoteJNJPositive Net Change
• ALXN Quick QuoteALXNPositive Net Change
• ILMN Quick QuoteILMNNegative Net Change
• ESALY Quick QuoteESALYPositive Net Change

J&J's (JNJ) Phase III Study for Invokana Halted Earlier

by Zacks Equity Research Published on July 17,2018

Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data.

• JNJ Quick QuoteJNJPositive Net Change
• ALXN Quick QuoteALXNPositive Net Change
• ILMN Quick QuoteILMNNegative Net Change
• ESALY Quick QuoteESALYPositive Net Change

J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)

by Zacks Equity Research Published on July 17,2018

A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

• JNJ Quick QuoteJNJPositive Net Change
• ALXN Quick QuoteALXNPositive Net Change
• ILMN Quick QuoteILMNNegative Net Change
• ESALY Quick QuoteESALYPositive Net Change

Pacira Focused on Exparel Development Amid Competition

by Zacks Equity Research Published on July 16,2018

Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.

• JNJ Quick QuoteJNJPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• ESALY Quick QuoteESALYPositive Net Change
• PCRX Quick QuotePCRXPositive Net Change

Zogenix (ZGNX) in Focus: Stock Moves 9.8% Higher

by Zacks Equity Research Published on July 16,2018

Zogenix (ZGNX) was a big mover last session, as the company saw its shares rise nearly 10% on the day.

• ESALY Quick QuoteESALYPositive Net Change
• ZGNX Quick QuoteZGNXNegative Net Change

Amgen Resubmits BLA to FDA for Osteoporosis Candidate Evenity

by Zacks Equity Research Published on July 13,2018

Amgen Inc. (AMGN) and its partner UCB announce the resubmission of the BLA to the FDA for Evenity to treat osteoporosis in postmenopausal women and in men at increased risk of fracture.

• MRK Quick QuoteMRKPositive Net Change
• HLUYY Quick QuoteHLUYYPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• ESALY Quick QuoteESALYPositive Net Change
• CCXI Quick QuoteCCXIPositive Net Change

J&J (JNJ) to Pay $4.69 Billion to Some Women in Talc Lawsuit

by Zacks Equity Research Published on July 13,2018

Johnson & Johnson (JNJ) has been ordered to pay $4.69 billion in damages to 22 families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.

• JNJ Quick QuoteJNJPositive Net Change
• HLUYY Quick QuoteHLUYYPositive Net Change
• ESALY Quick QuoteESALYPositive Net Change
• CCXI Quick QuoteCCXIPositive Net Change

Why Biotech Stocks Rallied on Biogen's Alzheimer's Test

by Ryan McQueeney Published on July 06,2018

Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.

• IBB Quick QuoteIBBNegative Net Change
• GILD Quick QuoteGILDNegative Net Change
• CELG Quick QuoteCELGPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• BIIB Quick QuoteBIIBNegative Net Change
• ESALY Quick QuoteESALYPositive Net Change

Eisai and Merck Announce Update on Lenvatinib sNDA Review

by Zacks Equity Research Published on May 25,2018

Eisai/Merck's (MRK) sNDA for cancer drug, lenvatinib, seeking approval for first-line treatment of HCC gets a three-month extension from the FDA.

• NVS Quick QuoteNVSPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• BAYRY Quick QuoteBAYRYPositive Net Change
• ESALY Quick QuoteESALYPositive Net Change

Ionis Pharmaceuticals (IONS) in Focus: Stock Moves 5.8% Higher

by Zacks Equity Research Published on April 23,2018

Shares of Ionis Pharmaceuticals (IONS) rose 5.8% on Friday.

• ESALY Quick QuoteESALYPositive Net Change
• IONS Quick QuoteIONSNegative Net Change

What Falling Estimates & Price Mean for Endo International (ENDP)

by Zacks Equity Research Published on April 03,2018

Endo International (ENDP) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

• ENDP Quick QuoteENDPPositive Net Change
• ESALY Quick QuoteESALYPositive Net Change

Shire (SHPG) Soars: Stock Adds 12.2% in Session

by Zacks Equity Research Published on March 29,2018

Shire (SHPG) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.

• ESALY Quick QuoteESALYPositive Net Change
• SHPG Quick QuoteSHPGNo Net Change

ImmunoGen (IMGN) Jumps: Stock Rises 7%

by Zacks Equity Research Published on March 27,2018

ImmunoGen (IMGN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

• ESALY Quick QuoteESALYPositive Net Change
• IMGN Quick QuoteIMGNPositive Net Change

Endocyte (ECYT) Catches Eye: Stock Jumps 7.7%

by Zacks Equity Research Published on March 13,2018

Endocyte (ECYT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

• ECYT Quick QuoteECYTNo Net Change
• ESALY Quick QuoteESALYPositive Net Change

Stock Market Roundup, March 12: Tech Stocks Gain, Dow Slumps

by Ryan McQueeney Published on March 12,2018

Stocks on Monday opened higher on lingering excitement over a "Goldilocks" economic situation, inspired by Friday's new jobs report. Nevertheless, the Dow and S&P 500 struggled to stay in the green.

• VEC Quick QuoteVECPositive Net Change
• NFLX Quick QuoteNFLXPositive Net Change
• ESALY Quick QuoteESALYPositive Net Change

New Strong Sell Stocks for December 26th

by Zacks Equity Research Published on December 26,2017

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

• WAIR Quick QuoteWAIRPositive Net Change
• SCS Quick QuoteSCSPositive Net Change
• HIG Quick QuoteHIGNegative Net Change
• ESALY Quick QuoteESALYPositive Net Change

New Strong Sell Stocks for November 30th

by Zacks Equity Research Published on November 30,2017

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

• FRC Quick QuoteFRCPositive Net Change
• UEIC Quick QuoteUEICPositive Net Change
• FNSR Quick QuoteFNSRPositive Net Change
• VRTS Quick QuoteVRTSPositive Net Change
• ESALY Quick QuoteESALYPositive Net Change

New Strong Sell Stocks for November 7th

by Zacks Equity Research Published on November 07,2017

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

• TSLA Quick QuoteTSLAPositive Net Change
• SMP Quick QuoteSMPPositive Net Change
• PHG Quick QuotePHGNegative Net Change
• ESALY Quick QuoteESALYPositive Net Change

Karyopharm's Liposarcoma Candidate Superior in Phase II Study

by Zacks Equity Research Published on September 21,2017

Karyopharm's (KPTI) selinexor reduced the risk of progression or death in previously treated patients with advanced dedifferentiated liposarcoma.

• JNJ Quick QuoteJNJPositive Net Change
• ALXN Quick QuoteALXNPositive Net Change
• ESALY Quick QuoteESALYPositive Net Change
• KPTI Quick QuoteKPTINegative Net Change

ChemoCentryx (CCXI) Catches Eye: Stock Moves Up 6.4%

by Zacks Equity Research Published on July 12,2017

ChemoCentryx, Inc. (CCXI) moved big last session, as its shares rose over 6% on the day.

• ESALY Quick QuoteESALYPositive Net Change
• CCXI Quick QuoteCCXIPositive Net Change

Affimed (AFMD) Looks Good: Stock Moves Up 8.7% in Session

by Zacks Equity Research Published on July 10,2017

Affimed N.V. (AFMD) moved big last session, as the company saw its shares rise over 8% on the day.

• ESALY Quick QuoteESALYPositive Net Change
• AFMD Quick QuoteAFMDNegative Net Change

MEI Pharma (MEIP) Worth a Look: Stock Rises 12% in Session

by Zacks Equity Research Published on July 07,2017

MEI Pharma, Inc. (MEIP) shares rose over 12% in the last trading session.

• ESALY Quick QuoteESALYPositive Net Change
• MEIP Quick QuoteMEIPNegative Net Change